Incyte INCB054828

Please note: The Incyte INCB054828 trial is no longer recruiting new patients. (August 2018)

A Phase 2, open-label, single-arm, multicentre international study to evaluate the efficacy and safety of the INCB054828 in patients with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma, including FGFR2 translocations, who failed previous therapy.

Inclusion criteria include tumour assessment for FGF/FGFR gene alteration status.

Now open and recruiting at Addenbrookes Hospital, Cambridge

Principal Investigator for this study at Addenbrooke’s: Dr Bristi Basu
Honorary Consultant Medical Oncologist

Addenbrooke’s Hospital
Department of Oncology
Box 193,  Hills Road
Cambridge CB2 0QQ

Secretary, Gill Stylianou, Department of Oncology
Tel: 01223 274401

These sites are now also open and recruiting patients as at 17.08.17:
Hammersmith Hospital, London
Lead: Dr Harpreet Wasan

Guys Hospital, London
Lead: Dr Debashis Sarker

Royal Bournemouth Hospital, Dorset
Lead: Dr Tamas Hickish

Aberdeen Royal Infirmary, Scotland
Lead: Dr Kathryn Connolly

It is planned that this trial will open at the following sites soon (correct as of 17.08.17):
Clatterbridge Cancer Centre, Liverpool
Lead: Prof Daniel Palmer

Weston Park Hospital, Sheffield
Lead: Dr Jonathan Wadsley

The Christie, Manchester
Lead: Dr Mairead McNamara

Beatson West of Scotland Cancer Centre
Lead: Prof Jeff Evans

Velindre Cancer Centre, Cardiff, Wales
Lead: Dr Kein Yim

Incyte Corporation Identifier:  NCT02924376

For more information go to:

Back to previous page